TAIHO PHARMA

Otsuka group of companies 100th Anniversary
Exploring hidden
possibilities for
people awaiting
new medicines

■We mourn the loss of those who have died from COVID-19, extend our sympathies to their loved ones, wish COVID-19 survivors rapid and permanent recoveries, and express our gratitude to medical professionals and others who support the ill.
■Otsuka Holdings Donations for Humanitarian Support to Ukrainian People

About Taiho

Becoming a truly global specialty pharma that meets the expectations of patients worldwide.

Our Business

Taiho Pharmaceutical creates innovative, highly valuable new drugs to support patients and the advancement of medicine, seeking to contribute to smiles and health for people all around the world.

News Releases

June 20, 2022

Taiho Pharmaceutical Obtains Approval to Manufacture and Market HSP90 inhibitor Jeselhy_® Tablets 40 mg (Pimitespib) for Gastrointestinal Stromal Tumor (GIST)
June 01, 2022

Taiho Pharmaceutical to Donate a Total of 4.17 Million Yen to Three Projects Addressing Issues in the Field of Oncology "The First Taiho Smile Support"
May 25, 2022

Taiho Pharmaceutical Announces the Launch of Selective NK₁ Receptor Antagonist Arokaris_® I.V. Infusion 235mg in Japan
May 12, 2022

Taiho Pharmaceutical and Cullinan Oncology Announce Strategic Collaboration to Jointly Develop and Commercialize CLN-081/TAS6417 and Taiho's Acquisition of Cullinan Pearl （PDF：139.2 KB）
April 21, 2022

Otsuka Group Joins RE100 International Initiative　- Committed to 100% Renewable Energy -

Information

May 13, 2022

Otsuka Holdings announces FY2022 Q1 financial results
July 12, 2018

Announcement of Support from Otsuka Holdings and Its Group Companies in the Aftermath of Severe Storms in Japan（PDF：165.9 KB）